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Thyrotoxicosis presenting during pregnancy is a common clinical problem and can be challenging to
differentiate between physiologic patterns of thyroid dysfunction during gestation and intrinsic hyper-
thyroidism. This review provides a summary of the differential diagnosis, clinical presentation, diagnostic
options, potential adverse effects of maternal thyrotoxicosis to the fetus, and treatment recommenda-
tions for thyrotoxicosis arising in pregnancy.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Metabolic disorders, including thyroid dysfunction, are among
the most common pre-pregnancy diseases in pregnant women [1].
Thyrotoxicosis presenting in pregnancy can be particularly chal-
lenging, given the normal physiologic changes which occur and
limitations of laboratory and radiologic testing during pregnancy.
Early recognition, accurate diagnosis, and appropriate management
of thyrotoxicosis during pregnancy are important for decreasing the
risks of adverse maternal and fetal outcomes.Differential diagnosis
Thyrotoxicosis during pregnancy is suggested by a suppressed
serum thyroid stimulating hormone (TSH). Hyperthyroidism is
thyrotoxicosis arising from the thyroid; subclinical hyperthyroid-
ism is deﬁned as a TSH concentration below the lower limit of the
reference range and normal free or total thyroxine (T4) and triio-
dothyronine (T3) concentrations, whereas overt hyperthyroidism isBY-NC-ND license (http://
11D), VA Greater Los Angeles
CA 90073, USA. Tel.: þ1 310
eung).
Inc. Open access under CC BY-NC-ND licedeﬁned as TSH concentration below the lower limit of the reference
range and elevated concentrations of serum T4 and T3 [2]. The most
common cause of thyrotoxicosis in pregnancy is gestational tran-
sient thyrotoxicosis (GTT), which occurs from the stimulatory ac-
tion of human chorionic gonadotropin (HCG) on the TSH receptor.
GTT is reported to have a prevalence of 2e3% in a European pop-
ulation [3]. However, this is variable, and in a study of 184 women
in Singapore, the prevalence of GTT during the ﬁrst trimester was
much higher at 11% [4]. GTT is also more common in patients with a
history of Graves’ disease prior to pregnancy, in whom the preva-
lence can be as high as 25% [5]. The prevalence of overt thyrotoxi-
cosis in pregnancy ranged from 0.2 to 0.7% in one large U.S.
population sample [6].
Other etiologies to consider in the differential diagnosis of
thyrotoxicosis during pregnancy include subtypes of overt hyper-
thyroidism, such as Graves’ disease, toxic multinodular goiter, and
toxic adenoma, as well as thyroiditis and exogenous thyroid hor-
mone use [6,7]. In addition, a rare cause of thyrotoxicosis during
pregnancy is trophoblastic disease. Molar pregnancies, which
include complete and partial hydatidiform moles, result from
abnormal genomic duplication associated with monospermic or
dispermic fertilization and subsequent loss of thematernal nuclear
genome [8]. The hyperthyroidism of trophoblastic disease is often
subclinical in nature; the incidence of symptomatic hyperthy-
roidism is very rare and conﬁned to small case series or case re-
ports [9,10].nse.
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The signs and symptoms of thyrotoxicosis in pregnancy are the
same as those in nonpregnant patients and can include anxiety,
tremor, heat intolerance, palpitations, weight loss or lack of weight
gain, goiter, tachycardia, and hyperreﬂexia [11,12]. Distinguishing
between GTT and intrinsic hyperthyroidism is important, given the
differences in their course and recommended management. The
duration and types of symptoms may help guide diagnostic de-
cisions. The presence of goiter, ophthalmopathy, and persistence of
disease can be suggestive of Graves’ disease [13,14]. In contrast, GTT
rarely manifests with signs and symptoms of overt hyperthyroid-
ism, but is more commonly associated with the persistent vomiting
of hyperemesis gravidarum [13,15]. The severity of hyperemesis
correlates with the degree of hyperthyroidism and usually resolves
by 18e19 weeks of gestation [13,16]. Symptomatic hyperthyroidism
is also rare in trophoblastic disease, in which the more common
manifestations are vaginal bleeding and a characteristic “snow-
storm pattern” on ultrasound of the uterine contents [8].
Thus, although certain signs and symptoms can provide clues to
the underlying etiology of thyrotoxicosis during pregnancy, they are
not speciﬁc to any one disease. This signiﬁcant overlap between
abnormal signs, symptoms, and physical exam makes laboratory
testing essential.
Diagnosis
Laboratory tests
TSH
Current guidelines by the American Thyroid Association,
American Association of Clinical Endocrinologists, and the Endo-
crine Society recommend that trimester-speciﬁc TSH ranges be
used in the evaluation of thyroid function during pregnancy, as
established from data of pregnant women [17e19]. Recommended
TSH ranges are 0.1e2.5mIU/L, 0.2e3.0mIU/L, and 0.3e3.0mIU/L for
the ﬁrst, second, and third trimesters, respectively [17e19]. The
lower end of TSH is not well-established in pregnancy, and normal
values can be as low as 0.02 mIU/L [20,21].
Free T4
The variability and lack of standardization of the serum free
thyroxine (FT4) analog (direct) immunoassay, which is that avail-
able in most commercial laboratories, limits its utility in the diag-
nosis and management of hyperthyroidism during pregnancy. In a
Danish study of two cohorts of pregnant women living in the same
region, measurements of FT4 concentrations by two different im-
munoassays were widely variable across all gestational age groups;
up to 100% of FT4 levels in one cohort were outside the reference
range of the other [22]. Similar variability is seen when using
different immunoassays for measuring FT4 concentrations on the
same serum sample [23].
Such variability makes it difﬁcult to establish pregnancy-speciﬁc
reference ranges for serum FT4 levels. Other techniques for assaying
FT4 levels, such as equilibrium dialysis and tandem mass spec-
trometry [24], are more accurate, but not widely available and
usually more costly.
Total T4, T3, and free T4 index
Given the lack of standardization of the FT4 assay and vari-
ability of its results, serum total thyroxine (T4) and triiodothyro-
nine (T3) levels are alternative options for assessing thyroid
function. Pregnancy is associated with increased thyroid binding
globulin (TBG) levels, due to the effect of estrogen on glycosylation
of TBG, and therefore, increased total T4 concentrations. Duringthe ﬁrst trimester, total T4 levels increase by approximately 50%
due to this physiologic effect [3]; the normal upper limit of serum
total T4 concentrations is set at 1.5 times that of the non-pregnant
normal upper limit [17,18,25,26]. The proposal for the use of total
thyroid hormone levels is not without controversy, as variations in
TBG concentrations and the lack of well-established pregnancy
reference range for serum total T4 levels are disadvantages [27]. In
a study of more than 17,000 women without thyroid disease,
after establishing normative values for serum total T4 levels, there
was an 88% agreement in identifying subclinical hypothyroidism
(SCH) when using either the free T4 immunoassay or total T4
assay [28].
Measurement of the free T4 index (FTI), which adjusts for the
presence of binding proteins, has also been proposed as an alternate
and perhaps more accurate test for diagnosing hyperthyroidism
[17]. However, trimester-speciﬁc reference ranges for FTI have only
been established in one study of 152 antibody-negative pregnant
womenwithout known thyroid disease in Iran, a region considered
to be generally iodine sufﬁcient [29].
TSH receptor antibodies
In pregnant patients undergoing evaluation for thyrotoxicosis,
measurement of serum TSH receptor antibodies (TRAb) is impor-
tant for both diagnostic and prognostic reasons. The presence of
antibodies, when evaluated concurrently with clinical ﬁndings, can
help differentiate Graves’ disease fromGTT [13]. In addition, TRAb is
able to cross the placental barrier to result in potentially adverse
outcomes, such as neonatal hyperthyroidism and hypothyroidism
[30,31]. The fetal thyroid gland begins to respond to the action of
TRAb at approximately 20 weeks of gestation, corresponding to the
decline of maternal TRAb titers due to gestational immune modu-
lation [32,33]. Serum TRAb measurements, when indicated, can be
used to guide the potential risk of fetal Graves’ disease and provide
important management decisions in utero.
According to guidelines by the European Thyroid Association,
the decision to measure serum TRAb titers should depend on risk
stratiﬁcation determined by current and past treatment of Graves’
disease [34]. As the risk of complications is low in euthyroid
women with Graves’ disease who are not receiving antithyroid
medication and have no history of radioiodine treatment or thy-
roidectomy, measuring serum TRAb levels is not indicated in such
patients. In women who are taking antithyroid medication, it is
recommended to measure serum TRAb concentrations in the third
trimester, and if there is history of radioiodine treatment, early in
pregnancy, regardless of thyroid function status [34]. Current
guidelines by the American Thyroid Association and the Endocrine
Society recommend measuring TRAb at 20e24 weeks of gestation
in patients with past or present history of Graves’ disease [17,18].
Serum TRAb titers can also be used to help differentiate between
postpartum thyrotoxicosis secondary to destructive thyroiditis and
Graves’ disease [35].
HCG
HCG plays an important role in the maintenance of the placenta,
withserumlevelspeakingat9e10weeksofpregnancy. It is composed
of an a-subunit that is identical with that of TSH, LH, and FSH. Due to
itsweak binding to the TSH receptor, serumHCG concentrations have
a thyrotrophic effect that results in the TSH suppression seen in
womenwith GTT [36,37]. Hyperemesis gravidarum is more common
inwomenwithGTT, and serumHCG levels not only correlatewith the
degree of biochemical thyroid function, but also with the severity of
hyperthyroidism by laboratory assessment [38]. Biochemical evi-
dence of hyperthyroidism can be seen with serum HCG levels of
100,000e500,000 IU/L, and clinical hyperthyroidism can resultwhen
levels greater than 500,000 IU/L are measured [9,39]. Severely
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disease and usually are the ﬁrst clue to suggest a molar pregnancy
upon initial presentation [9,36].
Imaging studies
Ultrasound
Although clinical presentation, serum thyroid function tests, and
serum thyroid antibody titers are usually sufﬁcient for diagnosis,
thyroid ultrasonography to assess thyroid volume and blood ﬂow
can be a helpful tool for differentiating Graves’ disease from
thyroiditis in the thyrotoxic pregnant woman [35,40]. If fetal
Graves’ disease is suspected, fetal thyroid ultrasonography can be
used to assess for a goiter and additionally, accelerated bone
maturation and sustained fetal tachycardia as signs suggestive of
fetal hyperthyroidism [41,42].
Thyroid nuclear medicine studies
Radioiodine uptake and scanning can lead to adverse fetal out-
comes, including those adverse effects associated with radiation
exposure to the developing fetus, as well as fetal hypothyroidism.
Thus, thyroid nuclear studies are contraindicated in pregnancy [43].
Adverse pregnancy outcomes of maternal hyperthyroidism
Mother and fetus
Overt hyperthyroidism (thyrotoxicosis arising from the thyroid
gland) during pregnancy can lead to poor maternal and fetal out-
comes. Maternal complications of pregnancy associated with hy-
perthyroidism include pre-term delivery, miscarriage,
hypertension, and heart failure [44,45].
In a recent report of 223,512 pregnancies from the U.S. Con-
sortium of Safe Labor, hyperthyroidism during pregnancy was
associated with 1.4-fold increased odds of induction of labor, a 1.8e
3.6-fold increased risk of preeclampsia, a 1.8-fold increased risk of
preterm births, and nearly a 4-fold increased risk of maternal ad-
missions to the intensive care unit following delivery, which
included mothers diagnosed with heart failure [6]. Although this
study did not include data regarding treatment of the maternal
hyperthyroidism, these complications are likely evenmore frequent
in women with poorly-managed hyperthyroidism. Severe compli-
cations of hyperthyroidism during pregnancy, such as maternal
heart failure, are associated with a lack of prenatal care or non-
adherence with antithyroid medications [45].
The fetal and neonatal complications of maternal hyperthyroid-
ism includegoiter formationandhyperthyroidism,which can lead to
intrauterine growth restriction and failure to thrive in the neonate
[46]. In a pregnant womanwith Graves’ disease fetal hyperthyroid-
ismcan result fromplacental transferof TRAb that stimulate the fetal
thyroid gland [31,42,47]. One report estimates that the frequency of
fetal hyperthyroidism ranges from 1 to 5% in women with Graves’
disease during pregnancy [48]. In particular, a signiﬁcantly elevated
serum TRAb concentration late in pregnancy is associated with an
increased risk of hyperthyroidism in the newborn [47]. Based on this
association, some clinicians measure maternal TRAb or Thyroid
Stimulating Immunoglobulin levels in the third trimester of preg-
nancy to identify those at increased risk of neonatal Graves’ disease.
More speciﬁcally, guidelines recommend measuring TRAb levels at
20e24weeks gestation [17,18]. Althoughmore rare, fetal or neonatal
hypothyroidism is also a known complication that can arise from
shifting in the balance between thyroid stimulating and thyroid
blocking antibodies [49]. Fetal hypothyroidism can also result from
the transplancental passage of antithyroid drugs [50]. Central
hypothyroidism is seen in some infants of mothers with elevated
thyroid hormone levels during pregnancy [51].Childhood outcomes
The adverse effects of hyperthyroidism during pregnancy on
long term outcomes are less clear. In a prospective cohort study that
assessed variations in serum thyroid function during pregnancy,
maternal overt hyperthyroidism in early pregnancy was not asso-
ciated with childhood body composition and adverse cardiovas-
cular outcomes [52]. In another study that evaluated maternal
thyroid dysfunction and associated attention deﬁcit hyperactivity
disorder (ADHD) and autism spectrum (ASD) disorders, there were
no associations of these diseases and treated maternal hyperthy-
roidism during pregnancy, compared towomenwith no preexisting
thyroid dysfunction [53].
Treatment
Thionamides
Current guidelines by the American Thyroid Association, the
American Association of Clinical Endocrinologists, and the Endo-
crine Society recommend the use of propylthiouracil (PTU) in the
ﬁrst trimester of pregnancy, and consideration to switch to
methimazole after the ﬁrst trimester [17,18,54]. These recommen-
dations are based on concerns of rare congenital abnormalities
associated with methimazole use during embryogenesis. In
breastfeeding mothers, antithyroid drugs (ATD) are considered safe
and can be used in moderate doses. The recommendation is to
administer ATD in divided doses immediately following each
feeding and for the breastfeeding infant to be monitored for po-
tential development of thyroid dysfunction [18].
In a retrospective study comparing treatment of pre-existing
Graves’ disease in the ﬁrst trimester with PTU, methimazole, and
no treatment, the relative risk of major congenital malformations
was signiﬁcantly higher in the methimazole group [55]. Congenital
malformations included aplasia cutis, omphalocele, symptomatic
omphalomesenteric duct anomaly and esophageal atresia.
Although there was a 2-fold increase in the odds of a congenital
malformation with methimazole treatment, the risk did not seem
to be dose-dependent. Similar ﬁndings were reported in a recent
large cohort study using a Danish nationwide registry. In this study
early pregnancy exposure was deﬁned as start of antithyroid
treatment from 6 months before pregnancy start to the end of the
10th gestational week. Both methimazole/carbimazole (MMI/CMZ)
and PTU exposure in early pregnancywere associatedwith 1.39 fold
increased risk of birth defects, with no signiﬁcant difference in the
overall prevalence of birth defects between the two treatment
groups. However, MMI/CMZ was associated with birth defects in
more organ systems compared to PTU, and a nearly 22-fold
increased risk of choanal atresia, esophageal atresia, omphalocele,
omphalomesenteric duct anomalies, or aplasia cutis compared to
nonexposed group. Furthermore, switching from MMI to PTU dur-
ing pregnancy did not decrease the risk of birth defects [56].
The potential reasons for the observed differences in fetal
congenital malformation rates regarding the use of speciﬁc thio-
namides is not clear. This does not seem to be related to differential
rates of placental passage, as one study reported that trans-
plancental cross-over was similar between methimazole and PTU
using an in-vitro assay of a perfused human term placental lobule
[57]. The small increased relative risks of neonatal complications
associated with methimazole may instead be related to the direct
action of each medication, and additional research is needed to
further understand this.
The choice of a thionamide in the treatment of maternal
hyperthyroidism during pregnancy involves balancing the risks of
adverse fetal outcomes with adverse maternal outcomes. Adverse
maternal outcomes can include drug rash, pruritus, and very rarely
hepatotoxicity [58]. While PTU is more hepatotoxic to the mother
A. Labadzhyan et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 140e144 143and fetus, it has a greater safety proﬁle regarding neonatal
congenital malformations.
Subtotal thyroidectomy
Thyroidectomy as a deﬁnitive treatment option for maternal
hyperthyroidism during pregnancy is recommended for patients
who are unable to tolerate antithyroid medications, require large
doses of these medications, or are nonadherent and have severe,
uncontrolled hyperthyroidism [18]. Thyroid surgery during the
second trimester is thought to be the safest option, although thy-
roid surgery during any time in pregnancy may confer an increased
risk of maternal complications, including higher rate of hypopara-
thyroidism, recurrent laryngeal nerve injury, and general surgical
complications [59].
Radioiodine therapy
Use of radioiodine (I-131) treatment during pregnancy is con-
traindicated, but can be an option prior to pregnancy. An important
consideration for patients treated with either radioiodine therapy
or thyroidectomy prior to pregnancy is the continued risk of
persistently elevated TRAb titers during pregnancy. In a prospective
randomized study, hyperthyroid patients treated with radioiodine
continued to have elevated serum TRAb titers one year following
treatment, while those who received antithyroid medication or
thyroid surgery had shorter durations of positive serum TRAb
concentrations [60]. In another retrospective study, use of radio-
iodine therapy prior to pregnancy was associated with a lower
incidence of postpartum thyrotoxicosis, which was thought to be
due to histological changes (various degrees of ﬁbrosis) in the
thyroid gland after radioiodine therapy and possible decrease in the
responsiveness of the remaining cells [61]. Women should be
counseled to avoid pregnancy for six months following radioiodine
therapy [18].
Conclusions
Thyrotoxicosis of pregnancy can present unique diagnostic
challenges and, if untreated, is associated with increased risks of
adverse maternal, fetal, and neonatal complications. The clinical
presentation, serum thyroid function test results, and serum TRAb
titers can help differentiate the etiology of thyrotoxicosis. However,
assessment and monitoring with serum thyroid function tests can
be difﬁcult, as there is signiﬁcant overlap between test results
arising from normal pregnancy physiology and intrinsic hyperthy-
roidism. Propylthiouracil is the preferred thionamide for treatment
of hyperthyroidism in the ﬁrst trimester. Radioiodine is contra-
indicated, and surgery, if indicated, should be performed during the
second trimester. Appropriate treatment of maternal hyperthy-
roidism during pregnancy and closemonitoring of mother and fetus
are essential for optimizing outcomes. Treatment should be tar-
geted to achieve serum TSH concentrations within established
pregnancy-speciﬁc reference ranges.
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